Holen Sie sich die Stockscreener-App
5.56
35.71%
1.43
Schlusskurs vom Vortag:
$4.13
Offen:
$5.37
24-Stunden-Volumen:
8.34M
Relative Volume:
7.45
Marktkapitalisierung:
$360.40M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-5.1481
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
+24.56%
1M Leistung:
+22.11%
6M Leistung:
-25.37%
1J Leistung:
-60.94%
1-Tages-Spanne:
$5.065
$6.13
1-Wochen-Bereich:
$4.10
$6.13
52-Wochen-Spanne:
$4.0913
$14.60
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.56 | 267.71M | 202.09M | -61.69M | -35.64M | -1.08 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Herabstufung | Needham | Buy → Hold |
| 2025-04-17 | Eingeleitet | BTIG Research | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
Evolus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Evolus Q4 2025 slides: revenue growth continues despite forecast miss By Investing.com - Investing.com Canada
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Aug Sectors: What analysts say about Evolus Inc stockTrade Risk Assessment & AI Enhanced Trading Alerts - baoquankhu1.vn
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips - Investing.com
Evolus Q4 Earnings Call Highlights - MarketBeat
Evolus Shares Up 17% on Q4, Full Year Earnings - Orange County Business Journal
Evolus, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-03-03 - Seeking Alpha
Evolus (EOLS) Q4 2025 Earnings Call Transcript - AOL.com
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Yahoo Finance
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans - Stock Titan
EOLS Projects Strong Financial Growth Through 2028 - GuruFocus
Evolus : Investor Presentation - marketscreener.com
Evolus Incenters loan and security agreement with Eclipse Business Capital on March 3, 2026SEC filing - marketscreener.com
EOLS Reports Strong Q4 Revenue Surpassing Expectations - GuruFocus
Evolus Posts Q4 Breakeven Results, Revenue Rises; Shares Gain After Hours - marketscreener.com
Evolus 2025 10-K: $297.2M Revenue, $(0.80) EPS - TradingView
Evolus Secures New Credit Facility and Reports Profitability - TipRanks
Evolus Q4 Earnings Summary & Key Takeaways - Benzinga
Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Evolus (NASDAQ: EOLS) wins $30M credit line and 12% 2025 sales rise - Stock Titan
Evolus, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
EOLS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Evolus recently officially disclosed its financial results for the fourth quarter and full year of 2025. - Bitget
Evolus Shares Earn 'Moderate Buy' Rating from Analysts - National Today
What to Expect from Evolus's Earnings - Benzinga
Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: A 237% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Evolus to join Leerink Partners Healthcare Conference for fireside chat and strategy talks - Traders Union
Evolus to Participate in The Leerink Partners Global Healthcare Conference - ChartMill
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Evolus (EOLS) Expected to Announce Earnings on Tuesday - MarketBeat
Aug Highlights: How volatile is CTEV stockTrend Reversal & High Accuracy Investment Entry Signals - baoquankhu1.vn
Evolus, Inc. (EOLS) Stock Analysis: A Potential 243% Upside Ignites Investor Interest - DirectorsTalk Interviews
Evolus (EOLS) awards RSUs and stock options to officer Rui Avelar - Stock Titan
Evolus (NASDAQ: EOLS) grants RSUs, PSUs and options to executive David Moatazedi - Stock Titan
How sustainable is Evolus Inc. stock dividend payoutWeekly Stock Recap & Intraday High Probability Setup Alerts - mfd.ru
Director at Evolus (EOLS) receives 45,559 restricted stock units in equity grant - Stock Titan
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead - Intellectia AI
Caligan exits Evolus (EOLS), amended filing shows 0% ownership - Stock Titan
Major holder Timothy P. Lynch reports 9.9% stake in Evolus (EOLS) - Stock Titan
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 - BioSpace
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - MSN
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 13, 2026 - BioSpace
How Evolus Inc. stock compares to growth peers2025 Volume Leaders & High Yield Equity Trading Tips - mfd.ru
Is Evolus Inc. undervalued by DCF analysis2025 Trade Ideas & High Conviction Buy Zone Picks - mfd.ru
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):